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Abstract
Background: Hyperfibrinolysis (HF) is a major contributor to coagulopathy and mortality in trauma patients. This
study investigated (i) the rate of HF during the pre-hospital management of patients with multiple injuries and (ii)
the effects of pre-hospital tranexamic acid (TxA) administration on the coagulation system.
Methods: From 27 trauma patients with pre-hospital an estimated injury severity score (ISS) ≥16 points blood was
obtained at the scene and on admission to the emergency department (ED). All patients received 1 g of TxA after
the first blood sample was taken. Rotational thrombelastometry (ROTEM) was performed for both blood samples,
and the results were compared. HF was defined as a maximum lysis (ML) >15 % in EXTEM.
Results: The median (min-max) ISS was 17 points (4–50 points). Four patients (15 %) had HF diagnosed via ROTEM
at the scene, and 2 patients (7.5 %) had HF diagnosed via ROTEM on admission to the ED. The median ML before
TxA administration was 11 % (3–99 %) vs. 10 % after TxA administration (4–18 %; p > 0.05). TxA was administered
37 min (10–85 min) before ED arrival. The ROTEM results before and after TxA administration did not significantly
differ. No adverse drug reactions were observed after TxA administration.
Discussion: HF can be present in severely injured patients during pre-hospital care. Antifibrinolytic therapy
administered at the scene is a significant time saver. Even in milder trauma fibrinogen can be decreased to critically
low levels. Early administration of TxA cannot reverse or entirely stop this decrease.
Conclusions: The pre-hospital use of TxA should be considered for severely injured patients to prevent the
worsening of trauma-induced coagulopathy and unnecessarily high fibrinogen consumption.
Trial registration: ClinicalTrials.gov ID NCT01938768 (Registered 5 September 2013).
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Background
Major trauma remains a leading cause of death world-
wide, particularly in younger people, with haemorrhage
accounting for approximately one third of all trauma-
related deaths [1, 2]. Trauma-associated coagulopathy
occurs early and is an important contributor to mortality
in severely injured patients [3]. The loss of coagulation
factors, together with the extensive activation of the coagu-
lation system due to release of tissue factor from injured
body regions can cause life-threatening coagulopathy,
which is an independent risk factor for trauma-associated
mortality [4, 5]. Hypothermia, acidosis, dilution after fluid
resuscitation and other factors contribute to trauma-
associated coagulopathy [5].
The activation of coagulation leads to the stimulation
of fibrinolysis by transformation of plasminogen to plasmin
[6]. As a result of the massive coagulation activation after
major trauma, the physiological process of fibrinolysis can
exceed fibrin formation, which can induce the breakdown
of freshly formed clots. This phenomenon, known as
hyperfibrinolysis (HF), impedes the formation of functional
clots and can become a major contributor to the con-
sumption of coagulation factors, in particular fibrino-
gen. Fibrinogen is the coagulation factor that first
reaches critically low levels in bleeding trauma patients
[7]. Therefore, HF contributes to the vicious circle of
haemorrhage, fibrinolytic activation and fibrinogen
consumption in bleeding trauma patients. However, the
exact point at which fibrinolysis extents fibrin forma-
tion and HF begins is unknown.
In a recent study of fibrinolysis, HF was diagnosed via
thrombelastometry (TEM) in 5 % of all trauma patients;
however 57 % showed moderate fibrinolysis with ele-
vated plasmin-antiplasmin (PAP) complex levels [8].
Other authors have reported that between 6 and 16 % of
trauma patients present with severe HF visible in TEM
[9–11]. HF in TEM is defined as a maximum lysis (ML)
exceeding 15 % of the maximum clot firmness (MCF)
[10]. The incidence and extent of HF in TEM and mea-
sured via PAP correlates with injury severity. HF is also
an independent contributor to mortality in major trauma
patients [8, 10, 12].
Tranexamic acid (TxA) inhibits fibrinolysis by blocking
the binding of lysine to plasminogen [6]. TxA was first in-
troduced as an antifibrinolytic drug in cardiovascular and
orthopaedic surgery. The results of the large CRASH-2
trial showed that the administration of TxA within the
first three hours after hospital admission reduced mor-
tality in trauma patients [2, 13]. Mortality rates were
lowest among patients who received TxA within the
first hour after hospital admission, and authors con-
cluded that TxA should be given as early as possible to
bleeding trauma patients [2]. Consequently, the early
administration of TxA must be included in the initial
clinical management of trauma patients [14]. Based on
the assumption that TxA should be administered as
early as possible to bleeding trauma patients, TxA has
been implemented in civilian and military emergency
medical services (EMSs) for immediate on-the-scene
administration [15, 16]. Nevertheless, a recent review
by Schoechl et al. revealed significant gaps in know-
ledge regarding the effects of pre-hospital TxA adminis-
tration. Apart from data obtained in military emergency
medicine, no current evidence supports the use of TxA
in pre-hospital emergency medicine [17].
TxA was implemented in the EMS of Göttingen,
Germany in December 2013. We conducted a prospective
observational study to investigate the effects of early pre-
hospital TxA administration among patients with multiple
injuries. Blood samples from trauma patients were col-
lected before the pre-hospital administration of TxA and
after arrival at the emergency department (ED), and the
results of the TEM measurements from both samples
were compared. We aimed to answer the following ques-
tions: (i) Is HF detectable by TEM at such an early stage
after major trauma? (ii) What are the effects of pre-
hospital TxA administration on the coagulation system?
Methods
Study design and data collection
This prospective observational study was part of a re-
search project investigating the effects of early TxA
administration during pre-hospital care that was ap-
proved by the Ethics Committee of the Medical Faculty
of the University of Göttingen (approval number 16/4/13).
Informed consent was obtained from patients following
their recovery from acute trauma. In cases of longer
lasting unconsciousness or disorientation, informed
consent was obtained from an officially appointed
guardian following the suspected will of the patient.
Based on the approval of the Ethics Committee, we did
not exclude patients who died during the first 72 h after
trauma. This study was registered at www.clintrials.gov
(NCT01938768).
Between December 2013 and August 2015, adult
trauma patients who were pre-hospitally attended by an
EMS emergency physician (EP) of the Department for
Anaesthesiology of the University Medical Centre of
Göttingen were included in this study. The inclusion
criteria were a diagnosis of major trauma with a pre-
hospitally assumed injury severity score (ISS) ≥16 points
[18] and the pre-hospital administration of 1 g TxA. The
exclusion criteria were age <16, refusal to consent, TEM
measurement delayed >4 h, TEM measurement <50 min,
and missing/insufficient blood samples. Patients who
died before hospital arrival were considered as intention-
to-treat and therefore not excluded.
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TxA was implemented at the Göttingen EMS in
December 2013, and the administration of 1 g of TxA is
part of the routine management of trauma patients at
risk for bleeding. For the rotational TEM (ROTEM)
measurements, a 3-ml blood sample was taken from
each patient who met the inclusion criteria as soon as
intravenous access was established and before the 1 g of
TxA was administered. A second 3-ml blood sample was
taken immediately after arrival at the ED, together with
the blood samples taken for routine laboratory investiga-
tions. Sample tubes containing 0.3 ml of buffered 3.2 %
trisodium citrate (S-Monovette®, Sarstedt AG & Co,
Nümbrecht, Germany) were used for blood sampling.
The data regarding patient demographics, time of in-
jury, time of EMS attendance, time of TxA administra-
tion, time of hospital arrival and the mechanisms of
injury were collected prospectively.
ROTEM analyses
The ROTEM measurements of both blood samples were
started within 2 h after arrival at the hospital using a
ROTEM delta® analyser (Tem International GmbH,
Munich, Germany). The working principle and parame-
ters of ROTEM were described previously [19]. From
each blood sample, four separate ROTEM assays were
started: EXTEM (coagulation activation by tissue factor
from rabbit brain), INTEM (coagulation activation by
ellagic acid), FIBTEM (coagulation activation by tissue
factor and inhibition of platelet function by cytochalasin D)
and APTEM (coagulation activation by tissue factor and
inhibition of fibrinolysis by TxA). The liquid reagents
star-tem®, ex-tem®, in-tem®, fib-tem® and t ap-tem®
(Tem International GmbH, Munich, Germany) were
used for all ROTEM analyses. Blood and reagents were
pipetted using the electronic pipette program of the
ROTEM device. Blood samples were stored in the 37 °C
warming plate of the ROTEM device until analysis.
The following parameters were measured and ana-
lysed: clotting time (CT, sec), MCF (mm), and ML (%).
The maximum clot elasticity (MCE, no dimension) was
calculated as MCE = (MCF – 100)/(100 – MCF). HF in
ROTEM was defined as an ML in EXTEM of >15 %.
Laboratory investigations and blood gas analyses
The following laboratory parameters were analysed from
the blood samples taken shortly after hospital arrival: pro-
thrombin time index (PTI, %), activated partial
thromboplastin time (aPTT, sec), fibrinogen concentra-
tion (measured using the Clauss method, optical read-
out, g/L), haemoglobin (Hb, g/dL), platelet count (PC,
103/μL), calcium (Ca2+, mmol/L), and PAP complex
(μg/L). Blood samples for standard laboratory investi-
gations were taken as part of the clinical routine and
analysed at the central laboratory facilities of the
University Medical Centre of Göttingen. The following
assays were used for the laboratory investigation: PTI
(RecombiPlasTin 2G, Instrumentation Laboratory
Company, Bedford, MA, USA), aPTT (SynthASil,
Instrumentation Laboratory Company, Bedford, MA,
USA), fibrinogen (Q.F.A. Thrombin [Bovine], Instru-
mentation Laboratory Company, Bedford, MA, USA),
Hb and PC (CELL-DYN Sapphire, Abbott Laboratories,
Abbott Park IL, USA), Ca2+ (AEROSET Calcium assay,
Abbot Laboratories, Abbott Park, IL, USA), PAP (PAP
micro ELISA, DRG Instruments GmbH, Marburg,
Germany). A blood gas analysis (BGA) is part of the
initial laboratory investigation of trauma patients upon
arrival to the ED. pH and lactate values were obtained
from the initial BGA (GEM 4000 blood gas analyser,
Instrumentation Laboratory Co., Bedford, MA, USA).
Statistical analyses
Descriptive analyses and significance testing were per-
formed using Statistica 10 (StatSoft Inc., Tulsa, USA).
All parameters were investigated for normal distribution
using the Kolmogorov-Smirnov test of normality. Signifi-
cance testing was performed using the independent-
samples t-test for normally distributed parameters and the
Mann-Whitney U test was applied for non-normally dis-
tributed parameters. P-values < 0.05 were considered as
significant.
Results
Thirty-two patients were eligible for this study. Five pa-
tients were excluded (one withdrew consent and four had
underfilled or diluted blood samples). The remaining 27
patients were enrolled, and their data were analysed ac-
cording to the study protocol. Table 1 summarises the
characteristics of the study population and the laboratory
findings upon hospital arrival. No adverse drug reactions
were observed during and after administration of TxA. No
major thromboembolic events were observed within
30 days after hospital admission.
The median time interval from injury to the arrival of
the TxA-carrying EP was 18 min (min-max: 4–65 min),
and TxA was administered a median time of 15 min
(7–53 min) later. Patients reached the ED 56 min
(25–128 min) after the arrival of the EP on the scene.
In median TxA was given 37 min (10–85 min) prior
to hospital arrival. Table 2 summarises these results.
The median duration of the ROTEM measurements
was 90:14 min:sec (52:25–90:29 min:sec). Prior to the
administration of TxA, HF in EXTEM was found in four
patients (15 %). The median ML in EXTEM prior to
receiving TxA was 11 % (3–99 %) (see Fig. 1). Upon
hospital arrival, HF in EXTEM was visible in two
patients (7.5 %), and the median ML was 10 % (4–18 %).
The differences in ML before and after the pre-hospital
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administration of TxA were not significant (p > 0.05).
Figure 2 summarizes these results. Table 3 summarizes
the results of the TEM analyses.
With a ML in EXTEM of 99 % prior to TxA adminis-
tration one patient showed complete clot breakdown in
ROTEM. This patient had the most severe HF in our
study and the effects of the early TxA administration are
therefore described more in detail: A TxA carrying EP
attended this patient ten minutes after the traumatic in-
cident. 15 min later 1 g of TxA was administered (the
blood sample for the first ROTEM had been collected
before). The ED was reached 39 min later (64 min after
injury). The patient had an ISS of 45. In the second
ROTEM analysis (after 1 g of TxA) the ML in EXTEM
was 4 %. The MCE in FIBTEM in the initial ROTEM
was 8 and 7 after hospital arrival.
Discussion
The present study investigated (i) whether severe HF oc-
curs during the initial on-the-scene management of
trauma patients and (ii) the effects of a pre-hospital TxA
administration on the coagulation system. As such, we
compared the TEM analyses of the blood samples from
trauma patients taken before the pre-hospital adminis-
tration of TxA and after arrival at the ED.
Overall, we found that HF was present in 15 % of pa-
tients prior to the administration of TxA. In our study,
three of four patients with ML >15 % had an ISS of ≥17
points. One patient with an ISS of eight points had an
ML of 20 % before the administration of TxA. Several
authors reported of associations between ISS and the in-
cidence and degree of HF [8, 10, 11]. Our findings sup-
port these observations, even during the early stages
following injury. Fibrinolytic activation seems to be part
of the early changes during trauma-associated coagulop-
athy and therefore contributes to fibrinogen consump-
tion from the beginning of the disorder. In their recently
published study, Theusinger et al. reported that 10 % of
trauma patients have a ML >15 % at the scene [11]. Our
data corroborate their observation that severely injured
patients can present with significant HF only minutes
after injury. Although only 55 % of the patients in the
study had an ISS ≥16 points we did observe critically
low fibrinogen levels in the first ROTEM analyses. With-
out treatment, the extent of fibrinolysis and fibrinogen
consumption will increase during pre-hospital treatment
and patient transportation, which was also demonstrated
by Theusinger et al., who did not administer TxA prior
to hospital admission, resulting in an HF rate that was
6 % higher upon hospital arrival [11]. In contrast, the
rate of HF was halved in our study, and only mild forms
of HF with a maximum ML of 18 % were present upon
hospital arrival. Because of the ongoing blood loss in
many situations the pre-hospital administration of TxA
will not be able to stop or even reverse the decrease of
fibrinogen in bleeding trauma patients. It can, however,
help to prevent unnecessary fibrinogen consumption
caused by fibrinolysis.
In our study, 1 g of TxA was given to patients with
multiple injuries immediately after intravenous access
Table 1 Patient demographics, injury severity, mechanisms of
injury and laboratory results
Patients (n = 27)
Age, median [min-max], years 50 [16–88]
Female, n (%) 5 (18.5)
Death before ICU admission, n (%) 1 (3.5)
30 d-survival, n (%) 24 (89)
ISSa, median [min-max], points 17 [4–50]
ISS ≥16 points, yes, n (%) 15 (55.5)
NISSa, median [min-max], points 17 [8–57]
NISS ≥16 points, yes, n (%) 18 (66.7)
Mechanisms of injury, n (%)
Road traffic accident (RTA) 14 (52)
RTA – motorcyclist 5 (18.5)
Fall 7 (26)
Other 1 (3.5)
First blood gas analysis on ED arrival, median [min-max]
pH 7.32 [6.84–7.39]
Haemoglobin, g/dL 12.9 [4.3–18.1]
Lactate, mmol/L 1.6 [1.1–15.6]
Base excess, mmol/L −0.3 [−18.9–4.8]
Calcium, mmol/L 1.2 [0.98–1.59]
Laboratory analyses on ED arrival, median [min-max]
PTI, % 91 [5–132]
aPTT, seconds 26 [21–180]
Fibrinogen, g/L 1.89 [0.47–4.79]
Platelets, ×103/μL 199 [15–354]
PAP complexb, μg/L 1837 [508–4815]
aISS according to the final results of clinical investigation and x-rays
(incl. CT scans)
bMissing data in three patients
Table 2 Time flow of EMS response, TxA administration and
ED arrival
Median time
[min, max]
Time to EP arrival (after injury) 18 min [4, 65]
Time to TxA administration (after injury) 32 min [17, 85]
Time to TxA administration (after EP arrival) 15 min [7, 53]
Time to hospital arrival (after injury) 74 min [31, 140]
Time to hospital arrival (after EP arrival) 56 min [25, 128]
Time to hospital arrival (after TxA administration) 37 min [10, 85]
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was established and the study blood samples had been
taken. Although TxA has no current marketing indica-
tion for use among major trauma patients, it is com-
monly used in clinical practice, and its administration is
recommended by current guidelines [20]. The recently
published NICE guidelines on the initial assessment and
management of major trauma patients do recommend
that TxA should be given as soon as possible. More-
over, based on the findings of the CRASH-2 trial, TxA
administration more than three hours after injury (not
hospital admission) is discouraged among major trauma
patients [2, 20]. Patients in our study received TxA in
median 32 min after injury. The median time until
hospital arrival was 74 min after injury. To our know-
ledge, no data are available regarding the timing of TxA
administration in pre-hospital emergency medicine.
Our results showed that the on-scene administration of
TxA leads to a significant time advantage for trauma
patients and supports the use of TxA as soon as possible
after injury. In some trauma patients (e.g., entrapped
patients after road traffic accidents and those requiring
long transportation distances), early administration of
TxA might in fact be the only option to ensure adminis-
tration within three hours after injury as recommended by
the guidelines.
Antifibrinolytic therapy should be given as soon as
possible when trauma patients are at risk of haemorrhage
and coagulopathy. The fast and secure identification of
such patients in pre-hospital care is therefore of particular
importance. TEM or fibrinolysis-specific laboratory tests
are not available in pre-hospital care. Thus, alternative
markers are needed that reliably identify high-risk trauma
patients.
Injury severity scoring systems such as the ISS and
NISS can be used as surrogates. Both can be estimated
during the pre-hospital management of trauma patients,
but due to the unavailability of radiological investiga-
tions, however, the risk for over- and underestimation is
high. Our study included trauma patients who were ini-
tially diagnosed with an ISS ≥16. According to our actual
routine management, these patients were considered as
at risk for haemorrhage and trauma-induced coagulopathy
and therefore received 1 g of TxA during pre-hospital
treatment. Based on the results of the clinical and radio-
logical investigations that were performed after hospital
admission, this diagnosis was correct for 55.5 % of our
patients. Obviously, the ISS was significantly overesti-
mated on the scene. Several authors have reported that
both EPs and paramedics overestimate injury severity in
pre-hospital care. Overestimation rates of up to 90 % have
been reported in the literature [21]. The overestimation
rate of 44.5 % regarding predicted injury severity in our
study was slightly better than those in the literature. More
research is needed to determine which trauma patients
benefit most from pre-hospital antifibrinolytic therapy.
Our data suggest that the estimation of injury severity by
an EP during pre-hospital management is poorly corre-
lated with the actual ISS and therefore does not appear to
be a suitable parameter for identifying high-risk patients.
Haemodynamic instability in trauma patients requiring
Fig. 1 ML in ROTEM on the scene (prior to TxA administration) and after ED arrival. No significant differences were found before and after the
administration of TxA (p > 0.05). In one patient no clot formatted in neither blood sample and therefore ML was not available
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vasopressors, epinephrine, or both might be considered as
a trigger for the pre-hospital use of TxA because high con-
centrations of epinephrine and vasopressin are known to
cause significant release of tissue plasminogen activator
(t-PA) from endothelial cells [22].
The results of the TEM analyses before and after TxA
administration did not show any significant differences
with regard to any of the relevant TEM parameters.
However, we were able to show that ML improved in all
patients with severe HF on the scene until hospital
arrival. Theusinger et al. reported significant changes in
the coagulation parameters between the blood samples
that were taken at the scene and those that were taken
at hospital admission. They investigated both plasma-
based coagulation parameters and ROTEM in trauma
patients. In their study, all coagulation parameters
significantly deteriorated over time (at the scene vs.
hospital arrival) [11]. In our study, no significant changes
were identified between the investigated TEM parame-
ters, although the median time to hospital arrival for our
patients was 29 min later than that in Theusinger et al.
The median ISS of 17 points was the same in both
Fig. 2 Results of the ROTEM analyses on the scene (prior to TxA administration) and after ED arrival: a CT in EXTEM, INTEM, FIBTEM and APTEM
b MCE in EXTEM, INTEM, FIBTEM and APTEM. No significant differences were found before and after the administration of TxA (p > 0.05)
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studies. However, because no coagulation-specific or
antifibrinolytic therapy was administered in their study,
the authors suggested that a “significant consumption of
fibrinogen” (and other coagulation factors) and “pro-
gressive fibrinolysis” took place between both measure-
ments [11]. In our study, we did not observe any
significant deterioration with regard to the relevant TEM
parameters following the administration of 1 g of TxA. In
particular, no significant decreases in MCE were observed
in EXTEM, INTEM and FIBTEM, nor did the CTs in-
crease in EXTEM and INTEM. Despite the limitations of
our small sample size and the heterogeneity of our study
population, our results suggest that early antifibrinolytic
therapy leads to less fibrinolytic activation, and therefore
lower fibrinogen consumption, resulting in an improved
function of the coagulation system at hospital admission.
Our study has several limitations. First, our sample
size was small. Thus, no subgroup analyses could be
performed (e.g., by different classes of injury severity).
Second, the administration of TxA in our study was part
of the routine management of trauma patients and
therefore random assignment and investigator blinding
were not possible. One team member took the blood
samples at the scene after arrival of the TxA-carrying
EP and during pre-hospital treatment. Although no
information was obtained regarding the fluid and
pharmacological therapy until the first blood sample
was taken, no patient received antifibrinolytic therapy
before the arrival of the TxA-carrying EP. Furthermore,
other than the administration of TxA, no information
was obtained regarding the fluid and pharmacological
therapy during pre-hospital treatment. TxA is the only
coagulation-specific medication carried by the Göttingen
EMS. No other blood products or coagulation factors
were administered during pre-hospital care. We detected
severe HF by assessing the ML in the TEM analyses. As
Raza et al. described, the PAP complex is a more sensitive
marker for mild and moderate HF [8]. In our study, PAP
was measured only at hospital arrival. In order to perform
this study without disturbing patient treatment, we
decided that no more than one blood sample container
should be taken during the initial treatment. Therefore,
we were unable to measure PAP before and after the
administration of TxA because this would have required
another separate blood sample.
To our knowledge, this study is the first that pros-
pectively investigated the influence of early pre-hospital
antifibrinolytic therapy on trauma patients in a non-
military environment. Our results found a significant
time advantage associated with the pre-hospital adminis-
tration of TxA and suggest that the resulting lower
fibrinolytic activation at the onset of the development of
trauma-associated coagulopathy leads to a better func-
tioning of the coagulation system upon hospital arrival.
More research is needed to investigate the influence of
pre-hospital antifibrinolytic therapy on other outcome
parameters, such as mortality, morbidity, therapy costs
or the need for blood products.
Conclusions
Severe HF can be present in trauma patients only minutes
after injury. Even in milder trauma (ISS <16 points)
fibrinogen can be decreased to critically low levels. Early
administration of TxA cannot reverse or entirely stop this
decrease. However, the pre-hospital administration of TxA
leads to a significant time advantage in the initiation of
antifibrinolytic therapy and probable is a highly effective
therapy of HF before hospital arrival. Additional research
is required to assess the effect of pre-hospital antifibrino-
lytic therapy on the outcome parameters. However, the
use of TxA during pre-hospital care should be considered
for severely injured patients to break the vicious circle of
haemorrhage, fibrinolytic activation and fibrinogen con-
sumption as early as possible.
Table 3 Results of the ROTEM analyses
Prior TxA ED arrival p-value
EXTEM
CT, median [min-max], sec 63 [47–348] 59 [44–2659] 0.97
MCF, median
[min-max], mm
59 [16–72] 57 [0–68]a 0.72
MCE, median [min-max] 143 [19–251] 136 [0–214]a 0.71
ML median [min-max], % 11 [0–99] 10 [4–18] 0.68
INTEM
CT, median [min-max], sec 136 [106–1039] 146 [107–2848] 0.22
MCF, median
[min-max], mm
55 [10–68] 56 [0–68]a 0.75
MCE, median [min-max] 124 [11–128] 130 [0–211]a 0.89
ML median [min-max], % 11 [2–81] 9 [3–18] 0.63
FIBTEM
CT, median [min-max], sec 55 [38–3600]a 56 [42–3600]a 0.94
MCF, median
[min-max], mm
12 [0–23]a 10 [0–21]a 0.29
MCE, median [min-max] 13 [0–31]a 11 [0–27]a 0.26
ML median [min-max], % 1 [0–97] 0 [0–10] 0.10
APTEM
CT, median [min-max], sec 58 [42–418] 62 [40–1349] 0.78
MCF, median
[min-max], mm
59 [15–71] 57 [5–67] 0.56
MCE, median [min-max] 142 [17–251] 133 [5–207] 0.54
ML, median [min-max], % 11 [0–20] 11 [3–19] 0.80
aif no clot formation was visible in TEM analyses CT was defined as 3600 sec
(minimal duration of TEM analyses). MCF and MCE were defined as 0
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